US$ 25.15
does pfizer have a glp-1 drug Pfizer's Push into GLP‑1 Drugs Signals New Era in Obesity Treatment — and a Pfizer to discontinue danuglipron, its
Description
Given the potential for increased INR variability, clinicians may consider increasing INR monitoring frequency following GLP-1 RA initiation

Wegovy, which seemed to sail smoothly, hit a snag after announcing follow-up data in May 2022
doi:10.1016/S0303-7207(01)00405-1 329

Bytzer P, Talley NJ, Leemon M, et al

PA and GHI also contributed to the writing of the manuscript
